ReviewNature reviews. Cancer2012
Future directions in cancer prevention.
Review in Nature reviews. Cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 1 synthesis or guideline pooled it, 242 citations in OpenAlex.
- Ecosystem Barriers and Facilitators Linked to the Fear of Cancer Recurrence: An Umbrella Review.International journal of environmental research and public health · 2024Pooled it
- Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.Annals of oncology : official journal of the European Society for Medical Oncology · 2018Trial
- Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Trial
- Interpretation of Epidemiological Studies on the Relationship Between Mobile Phone Use and Cancer.Epidemiologia (Basel, Switzerland) · 2026Article
- Epigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposure.Nature medicine · 2026Article
- Vaccine strategies for cancer prevention in Lynch syndrome: the potential of dendritic cell-based therapy.Familial cancer · 2026Review
- Strategies to target PD-1/PD-L1 in the tumor microenvironment.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Immune interception in cancer: prioritizing vaccination in high-risk and premalignant settings.Frontiers in immunology · 2026Article
- Article
- Genes driving three-dimensional growth of immortalized cells and cancer.Cell death & disease · 2025Article
- Aromatics from fossil fuels and breast cancer.iScience · 2025Review
- Characterizing tertiary lymphoid structures associated single-cell atlas in breast cancer patients.Cancer cell international · 2025Article
- Pharmacodynamics (PD), Pharmacokinetics (PK) and PK-PD Modeling of NRF2 Activating Dietary Phytochemicals in Cancer Prevention and in Health.Current pharmacology reports · 2025Review
- Interplay of p62-mTORC1 and EGFR signaling promotes cisplatin resistance in oral cancer.Heliyon · 2024Article
- Tumor diagnosis using carbon-based quantum dots: Detection based on the hallmarks of cancer.Bioactive materials · 2024Review
- The roles of FHL2 as a mechanotransducer for cellular functions in the mechanical environment.Frontiers in cell and developmental biology · 2024Review
- Localization, tissue biology and T cell state - implications for cancer immunotherapy.Nature reviews. Immunology · 2023Review
- Cucurbitacin E Exerts Anti-Proliferative Activity via Promoting p62-Dependent Apoptosis in Human Non-Small-Cell Lung Cancer A549 Cells.Current issues in molecular biology · 2023Article
- Article
- Cholesterol and breast cancer risk: a cohort study using health insurance claims and health checkup databases.Breast cancer research and treatment · 2023Article
49 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prevention of cancer remains the most promising strategy for reducing both its incidence and the mortality due to this disease. For more than four decades, findings from epidemiology, basic research and clinical trials have informed the development of lifestyle and medical approaches to cancer prevention. These include selective oestrogen receptor modulators and aromatase inhibitors for breast cancer, the 5-α-reductase inhibitors finasteride and dutasteride for prostate cancer, and the development of vaccines for viruses that are associated with specific cancers. Future directions include genetic, proteomic and other molecular approaches for identifying pathways that are associated with cancer initiation and development, as well as refining the search for immunologically modifiable causes of cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.